NCT05108987

Brief Summary

The overall purpose of the study is to test the effect of Noom on exercise and diet advice in adults with type 2 diabetes. The overarching hypothesis is that the use of Noom may promote better dietary adherence during an exercise program, thereby promoting greater weight loss and cardiometabolic health compared to lifestyle advice only. In particular, the investigators anticipate that changes in metabolic and vascular insulin sensitivity will correlate with glycemic control and blood pressure changes.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for not_applicable diabetes-mellitus-type-2

Timeline
Completed

Started Sep 2021

Longer than P75 for not_applicable diabetes-mellitus-type-2

Geographic Reach
1 country

3 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 25, 2021

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

October 26, 2021

Completed
10 days until next milestone

First Posted

Study publicly available on registry

November 5, 2021

Completed
4.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2025

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 28, 2026

Completed
Last Updated

June 15, 2025

Status Verified

June 1, 2025

Enrollment Period

4.3 years

First QC Date

October 26, 2021

Last Update Submit

June 11, 2025

Conditions

Keywords

type 2 diabetesdietexercisemobile applicationcardiometabolicmetabolic healthbehavioralvascular healthblood flowcontinuous glucose monitoring

Outcome Measures

Primary Outcomes (1)

  • Body Weight

    The primary outcome is changes in body weight pre- and post-intervention

    Over the course of 2 weeks.

Secondary Outcomes (2)

  • Glucose Tolerance

    Over the course of 2 weeks.

  • Flow-mediated dilation

    Over the course of 2 weeks.

Study Arms (2)

Morning Exercise

EXPERIMENTAL

If subjects are randomly assigned to this group, they will participate in exercise training in the morning at a moderate to hard intensity. Subjects will be asked to regularly engage in morning exercise while supervised for about 2 weeks.

Behavioral: Morning Exercise

Afternoon Exercise

ACTIVE COMPARATOR

If subjects are assigned to this group, they will participate in the same exercise program but after in the afternoon.

Behavioral: Afternoon Exercise

Interventions

Exercise at moderate to hard intensity will be performed in the morning for up to 10 sessions for about 1 hour under supervision in the morning.

Morning Exercise

Exercise at moderate to hard intensity will be performed in the morning for up to 10 sessions for about 1 hour under supervision in the afternoon.

Afternoon Exercise

Eligibility Criteria

Age30 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Male or female \>30 and \<70 years old.
  • Has a body mass index \>28 and \<45 kg/m2.
  • Previously diagnosed with T2DM.
  • Subjects currently taking medications that affect heart rate and rhythm (i.e. Ca++ channel blockers, nitrates, alpha- or beta-blockers).

You may not qualify if:

  • Morbidly obese patients (BMI \>46 kg/m2) and overweight/lean patients (BMI \<27 kg/m2)
  • Evidence of type 1 diabetes and diabetics requiring insulin therapy
  • Subjects who have not been weight stable (\>2 kg weight change in past 3 months)
  • Subjects who have been recently active (\>30 min of moderate/high intensity exercise, 2 times/week).
  • Subjects who are smokers or who have quit smoking \<1 years ago
  • Subjects with abnormal estimated glomerular filtration rate (eGFR).
  • Hypertriglyceridemic (\>400 mg/dl) and hypercholesterolemic (\>260 mg/dl) subjects
  • Hypertensive (\>160/100 mmHg)
  • Subjects with a history of significant metabolic, cardiac, congestive heart failure, cerebrovascular, hematological, pulmonary, gastrointestinal, liver, renal, or endocrine disease or cancer that in the investigator's opinion would interfere with or alter the outcome measures or impact subject safety.
  • Pregnant (as evidenced by positive urine pregnancy test) or nursing women
  • Subjects with contraindications to participation in an exercise training program
  • Currently taking active weight suppression medication (e.g. phentermine,orlistat, lorcaserin, naltrexone-bupropion in combination, liraglutide, benzphetamine, diethylpropion, phendimetrazine)
  • Known hypersensitivity to perflutren (contained in Definity)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

New Jersey Institute for Food, Nutrition, and Health

New Brunswick, New Jersey, 08901, United States

RECRUITING

Robert Wood Johnson University Hospital Clinical Research Center

New Brunswick, New Jersey, 08901, United States

RECRUITING

Rutgers University Loree Gymnasium

New Brunswick, New Jersey, 08901, United States

RECRUITING

MeSH Terms

Conditions

Diabetes Mellitus, Type 2Metabolic SyndromeMotor ActivityBehavior

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesInsulin ResistanceHyperinsulinism

Study Officials

  • Steven K Malin, PhD

    Rutgers University - New Brunswick

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

October 26, 2021

First Posted

November 5, 2021

Study Start

September 25, 2021

Primary Completion

December 31, 2025

Study Completion

February 28, 2026

Last Updated

June 15, 2025

Record last verified: 2025-06

Data Sharing

IPD Sharing
Will not share

Locations